Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Fludarabine–mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma (1997)
    Springer
    Annals of oncology 8 (1997), S. 379-383 
    Details
    ISSN: 1569-8041
    Keywords: fludarabine ; mitoxantrone ; non-Hodgkin's lymphoma ; response rate
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: The promising results of fludarabine (FLU) in chroniclymphocytic leukemia have prompted its extensive evaluation in low-gradenon-Hodgkin's lymphoma (LG-NHL). Its different mechanisms of action make FLUan attractive partner for combination with other cytostatic agents. Patients and methods: We used a three-drug combination of FLU (25mg/m2 i.v. on days one to three), mitoxantrone (10mg/m2 i.v. on day one) and prednisone (40 mg per os on daysone to five) (FMP) to treat 48 patients with recurrent LG-NHL. Results: Of the 48 patients, 17 (35%) achieved complete responses(CR), 23 (48%) partial responses, while the remaining 8 (17%)showed no benefit from the treatment. The risk of lower CR rate wassignificantly correlated with the presence of advanced stage (IV) (P = 0.01),the number of previous regimens (〉3) (P = 0.006), and the follicularhistologic subtype (P = 0.02). The major toxic effects observed wereneutropenia and infections; there was only one fatality, due to drug-relatedside effects. Conclusions: These data confirm the significant efficacy of the FMPfludarabine-mitoxantrone combination regimen in obtaining a good remissionrate with moderate toxicity in a particular subset of recurrent LG-NHL.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008228709612
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    The role of positron emission tomography (PET) in the management of lymphoma patients (1999)
    Springer
    Annals of oncology 10 (1999), S. 1181-1184 
    Details
    ISSN: 1569-8041
    Keywords: abdominal mass ; aggressive NHL ; CT scan ; HD ; PET
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Treatment of both Hodgkin's disease (HD) and aggressive non-Hodgkin's lymphoma (NHL) with abdominal presentation at the time of diagnosis is often followed by detection of residual masses by computed tomography (CT). However, CT is usually unable to disciminate between residual tumor and fibrosis/necrosis. We investigated the ability of fluorine-18 fluorodeoxyglucose positron emission tomography (PET) to differentiate between residual active tumor tissue and fibrosis. Patients and methods: Forty-four patients with HD or aggressive NHL presenting abdominal involvement (41% with bulky mass) were studied with CT and PET at the end of chemotherapy ± radiation therapy. Results: After treatment, seven patients had negative PET and CT, and none of them relapsed. The remaining 37 patients all had positive CT (abnormalities ≤10%). All of the 13 who also had positive PET relapsed (100%). By contrast, there was only 1 (4%) relapse among the 24 patients who were positive at CT but negative at PET. The two-year actuarial relapse-free survival rate was 95% for those with negative PET compared with 0% for positive PET patients (P 〈 0.000000). Conclusions: In lymphoma patients with abdominal masses who present CT positivity at restaging, PET should be considered the noninvasive imaging modality of choice for differentiating early recurrences or residual disease from fibrosis.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1008327127033
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...